Abstract
A soluble activity inhibiting over 50% of the CTLL-2 cell line response to recombinant human interleukin 2 (IL 2) was found in 17 of 29 (59%) rheumatoid synovial fluids. To study the prognosis value of this activity, 16 rheumatoid synovial fluids were collected before a radiation synovectomy of the knee with 7 mCi of90Yt. Patients with a good clinical result after the synovectomy had a lower IL 2 inhibitory activity than those with a bad or uncomplete result (P<0.01). Levels of inhibitory activity and of soluble IL 2 receptors were correlated with each other and with the response of the synovitis to the radiation synovectomy. These results extend the clinical usefulness of soluble IL 2 receptor measurements and indicate a correlation between the immune activation of the rheumatoid synovitis and its clinical activity.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Kurozaka M, Ziff M: Immunoelectron microscopic study of the distribution of T cell subsets in rheumatoid synovium. J Exp Med 158:1181–1210, 1983
Talal N, Flescher E: Rheumatoid arthritis: An editorial perspective based on cytokine imbalance. J Autoimmun 1:309–318, 1988
Firestein GS, Xu WD, Townsend K, Broide D, Alvaro-Gracia J, Glasebrook A, Zvaifler NJ: Cytokines in chronic inflammation arthritis. I. Failure to detect T cell lymphokines (Interleukin 2 and Interleukin 3) and presence of macrophage colony-stimulating factor (CSF-1) and a novel mast cell growth factor in rheumatoid synovitis. J Exp Med 168:1573–1586, 1988
Hemler ME, Glass D, Coblyn JS, Jacobson JG: Very late activation antigens on rheumatoid synovial fluid T lymphocytes. Association with stages of T cell activation. J Clin Invest 78:696–702, 1986
Miossec P, Kashiwado T, Ziff M: Inhibitor of interleukin 2 in rheumatoid synovial fluid. Arth Rheum 30:121–129, 1987
Emery P, Gentry KC, Kelso A, Mackay IR: Interleukin 2 inhibitor in synovial fluid. Clin Exp Immunol 72:60–66, 1988
Rubin LA, Kurman CC, Fritiz ME, Biddison WE, Boutin B, Yarchoan R, Nelson DL: Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. J Immunol 135:3172–3177, 1985
Keystone EC, Snow KM, Bombardier C, Chang CH, Nelson DL, Rubin LA: Elevated soluble interleukin-2 receptor levels in the sera and synovial fluids of patients with rheumatoid arthritis. Arth Rheum 31:844–849, 1988
Campen DH, Horwitz DA, Quismorio FP, Ehresmann GR, Martin WJ: Serum levels of interleukin 2 receptor and activity of rheumatic diseases characterized by immune system activation. Arth Rheum 31:1358–1364, 1988
Ropes MW, Bennett GA, Cobb S, Jacox R, Jessar RA: 1958 revision of diagnostic criteria for rheumatoid arthritis. Bull Rheum Dis 9:175–176, 1958
Olive D, Raymond J, Dubreuil P, Charnot D, Jacques Y, Mawas C: Anti-interleukin 2 receptor monoclonal antibodies: Respective role of epitope mapping and monoclonal antibody-receptor interactions in their antagonist effects on IL 2 dependent T cell growth. Eur J Immunol 10:611–616, 1986
Jacques Y, Le Mauff B, Boeffard F, Godard A, Soulillou JP: A soluble interleukin 2 receptor produced by a normal alloreactive human T cell clone binds interleukin 2 with low affinity. J Immunol 139:2308–2316, 1987
Miyasaka N, Nakamura T, Russel IJ, Talal N: Interleukin 2 deficiencies in rheumatoid arthritis and systemic lupus erythematosus. Clin Immunol Immunopathol 31:109–117, 1984
Miyasaka N, Murota K, Yamaoka K, Sato K, Yamada T, Nishido T, Okuda M: Interleukin 2 defect in the peripheral blood and the lung in patients with Sjogren's syndrome. Clin Exp Immunol 65:497–505, 1986
Nath I, Jayaraman J, Sathish M, Bhutani LK, Sharma AK: Inhibition of interleukin-2 production by adherent cell factors from lepromatosous leprosy patients. Clin Exp Immunol 58:531–538, 1984
Spiegel JP, Djeu JY, Stocks NI, Masur H, Gelmann EP, Quinnan GV Jr: Sera from patients with acquired immunodeficiency syndrome inhibit production of interleukin-2 by normal lymphocytes. J Clin Invest 75:1957–1964, 1985
Prince HE, Kleinman S, Williams AE: Soluble IL 2 receptors levels in serum from blood donors seropositive for HIV. J Immunol 140:1139–1141, 1988
Symons JA, Wood NC, Di Giovine FS, Duff GW: Soluble IL 2 receptors in rheumatoid arthritis. Correlations with disease activity, IL 1 and IL 2 inhibition. J Immunol 141:2612–2618, 1988
Fava R, Olsen N, Keski-Oja J, Moses H, Pincus T: Active and latent forms of transforming growth factor β activity in synovial effusions. J Exp Med 169:291–296, 1989
Kehrl JH, Wakefield LM, Roberts AB, Jakowlew S, Alvarez-Mon M, Derynk R, Sporn MB, Fauci AS: Production of transforming growth factor β by human T lymphocytes and its potential role in the regulation of T cell growth. J Exp Med 163:1037–1050, 1986
Lotz M, Carson D: Transforming Growth Factor β and cellular immune responses in synovial fluids. Arth Rheum 32:S42, 1989
Flescher E, Bowlin TL, Ballester A, Houk R, Talal N: Increased polyamines may downregulate interleukin 2 production in rheumatoid arthritis. J Clin Invest 83:1356–1362, 1989
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Miossec, P., Elhamiani, M., Chichehian, B. et al. Interleukin 2 (IL 2) inhibitor in rheumatoid synovial fluid: Correlation with prognosis and soluble IL 2 receptor levels. J Clin Immunol 10, 115–120 (1990). https://doi.org/10.1007/BF00918193
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00918193